China (Mainland) 
quick detail:
product name:sorafenib tosylate
other name:sorafinib mesylate;1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-((2- (methylcarbamoyl)pyridin-4-yl)oxy)phenyl)urea mono(4- methylbenzenesulfonate);4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-n-(5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide monomethanesulfonate
cas:475207-59-1
mf:c21h16clf3n4o3.c7h8so3
mw:637.03
assay:99%min
appearence:white crystalline powder
drug category:anticancer drug
purpose:this product is mainly used for the treatment of liver and renal cell carcinoma of the clinical anti-cancer agents.
package:1kg/bag
function&usage:
sorafenib tosylate, also named nexavar, is a small-molecule anticancer compound. it is also a novel oral raf kinase and a vascular endothelial receptor (vegfr) inhibitor. it inhibits tumor cell proliferation and tumor angiogenesis [2]. to hepg2 cells (1× 106), the ic50 of sorafenib tosylate is 2.09μg/ml.
raf is a mitogen-stimulated protein kinase that functions as a component of the signaling cascade that leads to the stimulation of mitogen-activated protein kinase.
vascular endothelial (vegf) is a highly specific mitogen for vascular endothelial cells.
treatment with nexavar potently inhibited the cell proliferation of mv4-11 cells (flt3-itd) in a dose-dependent manner with an ic50 of 0.88 nm. in mv4-11 cells, sorafenib tosylate of a concentration of 100 nm induced 43.6±5.2% of the cells to undergo apoptosis whereas in eol-1 cells a concentration as low as 10 nm induced 89.29±1.8% of the cells to be apoptotic.
nude rats at the age of 6 weeks injected with 105 mda-mb-231 cells were involved. after monotherapy with sorafenib tosylate a significant reduction of the osteolytic lesion volume was observed on days 45 and 55 and of the soft tissue component volume on day 55 in comparison to untreated animals (p < 0.05). compared to controls, treatment with sorafenib tosylate made bone metastases show significantly decreased values of amplitude a and kep from day 35 to 55 (amplitude a: p<0.01; kep p<0.01 on days 35 and 55; p<0.05 on day 45)
coa:
| items of analysis |
specification |
results |
| description | off-white powder | conforms |
| loss on drying | nmt 1.0% | 0.7% |
| water content | nmt 0.5% | 0.13% |
| single impurity | nmt0.1% | 0.07% |
| total impurity | nmt 0.5% | 0.29% |
| purity(hplc) | nlt 99.0% | 99.71% |
| conclusion | qualified | |
 |